0001395064-21-000211.txt : 20211021 0001395064-21-000211.hdr.sgml : 20211021 20211021204037 ACCESSION NUMBER: 0001395064-21-000211 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20211021 FILED AS OF DATE: 20211021 DATE AS OF CHANGE: 20211021 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: TAKEDA PHARMACEUTICAL CO LTD CENTRAL INDEX KEY: 0001395064 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40925 FILM NUMBER: 211338422 BUSINESS ADDRESS: STREET 1: 1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU CITY: TOKYO STATE: M0 ZIP: 103-8668 BUSINESS PHONE: 81332782111 MAIL ADDRESS: STREET 1: 1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU CITY: TOKYO STATE: M0 ZIP: 103-8668 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Takeda Ventures, Inc. CENTRAL INDEX KEY: 0001771657 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40925 FILM NUMBER: 211338421 BUSINESS ADDRESS: STREET 1: 9625 TOWNE CENTRE DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 619-930-8101 MAIL ADDRESS: STREET 1: 9625 TOWNE CENTRE DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Xilio Therapeutics, Inc. CENTRAL INDEX KEY: 0001840233 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 851623397 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 828 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 617-833-1027 MAIL ADDRESS: STREET 1: 828 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 3 1 wf-form3_163486321236685.xml FORM 3 X0206 3 2021-10-21 0 0001840233 Xilio Therapeutics, Inc. XLO 0001395064 TAKEDA PHARMACEUTICAL CO LTD 1-1, NIHONBASHI-HONCHO 2-CHOME CHUO-KU, TOKYO M0 103-8668 JAPAN 0 0 1 0 0001771657 Takeda Ventures, Inc. 9625 TOWNE CENTRE DRIVE SAN DIEGO CA 92121 0 0 1 0 Series B Preferred Stock Common Stock 1248180.0 I See explanation Series C Preferred Stock Common Stock 226941.0 I See explanation These shares of the Issuers preferred stock are expected to convert on a one-for-one basis into the number of shares of the Issuers common stock, par value $0.0001 per share (Common Stock), shown in Column 3 immediately upon the closing of the Issuers initial public offering without payment of additional consideration. These shares of the Issuers preferred stock have no expiration date. This statement is being filed jointly by Takeda Pharmaceutical Company Limited and Takeda Ventures, Inc. Takeda Pharmaceutical Company Limited's beneficial ownership of the reported securities is comprised of the 1,248,180 Series B Preferred Stock held by Takeda Ventures, Inc. Takeda Ventures, Inc., is a direct, wholly owned subsidiary of Takeda Pharmaceuticals U.S.A. Inc., which is a direct subsidiary of Takeda Pharmaceutical Company Limited (72.70%) and Takeda Pharmaceuticals International AG (27.3%). Takeda Pharmaceuticals International AG is a direct, wholly owned subsidiary of Takeda Pharmaceutical Company Limited. Takeda Pharmaceutical Company Limited's beneficial ownership of the reported securities is comprised of the 226,941 Series C Preferred Stock held by Takeda Ventures, Inc. /s/ Yoshihiro Nakagawa, Corporate Officer, Global General Counsel of Takeda Pharmaceutical Company Limited 2021-10-21 /s/ Michael Martin, President of Takeda Ventures, Inc. 2021-10-21